Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Drug-Drug Interactions and Therapeutic Drug Monitoring
share announcement

Drug-Drug Interactions and Therapeutic Drug Monitoring

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 2883

Special Issue Editor

Dr. Chadi Abbara

E-Mail
Guest Editor
Pharmacology-Toxicology Department, Angers University Hospital, Angers, France
Interests: PPK/PD modeling; pharmacometrics; DDI; TDM; cancer therapy; psychopharmacology; bioanalytical method development

Special Issue Information

Dear Colleagues,

Therapeutic drug monitoring (TDM) is the clinical practice of drug quantification at designated intervals in patients’ blood samples, thereby improving the individual benefit/risk balance and avoiding the adverse drug reactions due to drug–drug interactions. The process of TDM is based on the assumption of a definable relationship between the pharmacokinetics (PK) and the pharmacodynamics (PD) of the drug. Drugs’ PK and/or PD can also be affected by demographic and biological co-variates. Hence, TDM aims to evaluate all these parameters to improve clinical outcomes. New statistical approaches and tools can be used for treatment individualization. The aim of this Special Issue is to highlight current research and tools leading to the development of TDM and treatment individualization.

Dr. Chadi Abbara
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacokinetics
  • pharmacodynamics
  • TDM
  • DDI
  • machine learning
  • bayesian estimation

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 2338 KiB  
Article
Prediction of the Drug–Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model
by Zhuodu Wei, Hyeon-Cheol Jeong, Min-Gul Kim and Kwang-Hee Shin
Pharmaceuticals 2023, 16(3), 360; https://doi.org/10.3390/ph16030360 - 26 Feb 2023
Cited by 1 | Viewed by 2563
Abstract
Tegoprazan is a novel potassium-competitive acid blocker. This study investigated the effect of drug–drug interaction on the pharmacokinetics and pharmacodynamics of tegoprazan co-administered with amoxicillin and clarithromycin, the first-line therapy for the eradication of Helicobacter pylori, using physiologically based pharmacokinetic and pharmacodynamic [...] Read more.
Tegoprazan is a novel potassium-competitive acid blocker. This study investigated the effect of drug–drug interaction on the pharmacokinetics and pharmacodynamics of tegoprazan co-administered with amoxicillin and clarithromycin, the first-line therapy for the eradication of Helicobacter pylori, using physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) modeling. The previously reported tegoprazan PBPK/PD model was modified and applied. The clarithromycin PBPK model was developed based on the model provided by the SimCYP® compound library. The amoxicillin model was constructed using the middle-out approach. All of the observed concentration–time profiles were covered well by the predicted profiles with the 5th and 95th percentiles. The mean ratios of predicted to observed PK parameters, including the area under the curve (AUC), maximum plasma drug concentration (Cmax), and clearance, were within the 30% intervals for the developed models. Two-fold ratios of predicted fold-changes of Cmax and AUC from time 0 to 24 h to observed data were satisfied. The predicted PD endpoints, including median intragastric pH and percentage holding rate at pH above 4 or 6 on day 1 and day 7, were close to the corresponding observed data. This investigation allows evaluation of the effects of CYP3A4 perpetrators on tegoprazan PK and PD changes, thus providing clinicians with the rationale for co-administration dosing adjustment. Full article
(This article belongs to the Special Issue Drug-Drug Interactions and Therapeutic Drug Monitoring)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop